Why GLP-1 weight loss plateaus: what the trials show

Key takeaways

• GLP-1 weight curves drop steeply, then flatten. STEP-1 (semaglutide 2.4 mg, 68 weeks) reached about -14.9 percent . SURMOUNT-1 (tirzepatide 15 mg, 72 weeks) reached about -20.9 percent . STEP-5 showed the nadir arrives around week 60 and holds through week 104 .
• The plateau is physiological: GLP-1 receptor desensitization , adaptive thermogenesis , and partial recovery of appetite.
• Multi-receptor agents reach lower nadirs and still plateau: tirzepatide (GLP-1 plus GIP) , retatrutide (GLP-1 plus GIP plus glucagon) , and CagriSema (GLP-1 plus amylin) .
• Stopping the drug brings the weight back. The STEP-1 extension showed about two-thirds regain by week 120 , and SURMOUNT-4 showed the same pattern for tirzepatide . This is long-term management, the way high blood pressure is managed.
• Three published levers bend the curve, covered below: dose escalation within label, multi-receptor combinations, and resistance training with higher protein during the active loss phase.

What the GLP-1 weight curve actually looks like

Public discussion treats GLP-1 weight loss as a steady decline. The registration trials show a steep early drop that flattens well before treatment ends. STEP-1 (semaglutide 2.4 mg weekly) reported a mean weight reduction of about 14.9 percent over 68 weeks, with most of the loss banked in the first 40 to 60 weeks . SURMOUNT-1 (tirzepatide 5, 10, and 15 mg weekly) had the same shape, reaching about 20.9 percent at the 15 mg dose by week 72 before slowing .

STEP-5 ran semaglutide out to 104 weeks. Weight loss plateaued after approximately week 60 and was maintained for the rest of the study, so the curve does not keep falling . The plateau repeats across compounds, doses, populations, and trial designs. A limit this reproducible is built into the biology.

Named trial nadirs by compound

• Semaglutide 2.4 mg (STEP-1, 68 weeks): mean -14.9 percent body weight .
• Semaglutide 2.4 mg (STEP-5, 104 weeks): mean -15.2 percent, with the nadir around week 60 .
• Tirzepatide 15 mg (SURMOUNT-1, 72 weeks): mean -20.9 percent .
• Tirzepatide, maximum tolerated dose 10 or 15 mg (SURMOUNT-3, 12-week lifestyle lead-in then 72 weeks on drug): mean -18.4 percent additional weight loss from randomization to week 72, on top of the lead-in loss .
• Retatrutide 12 mg (phase 2, 48 weeks): mean -24.2 percent body weight; too short to show a plateau .
• CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg, REDEFINE-1, 68 weeks): mean -22.7 percent on the trial-product estimand, about -20.4 percent on the treatment-policy estimand .

The receptor side: desensitization and multi-receptor coverage

GLP-1 receptor agonists slow gastric emptying, blunt postprandial glucose excursions, and act on hypothalamic and brainstem circuits (arcuate nucleus POMC neurons, area postrema) that reduce appetite. Sustained agonist exposure shifts receptor density and downstream signaling. Cell studies show the GLP-1 receptor desensitizes and internalizes within minutes of activation . Dual agonists like tirzepatide add GIP-receptor activity, a second pathway that may blunt some of that adaptation, which is one proposed reason they reach lower nadirs.

Multi-receptor compounds push the curve further before it bends. Tirzepatide (GLP-1 plus GIP) reaches a lower nadir than semaglutide . Retatrutide (GLP-1 plus GIP plus glucagon) reached a lower nadir than tirzepatide in its 48-week phase 2 trial . Its largest phase 3 obesity trial (TRIUMPH-1, NCT05929066) has since read out: Lilly's May 2026 topline announcement, a manufacturer summary with peer-reviewed data still to come, reported mean weight loss of 28.3 percent over 80 weeks on the 12 mg dose in 2,339 adults without diabetes . More receptor coverage lowers the nadir. It does not remove the plateau.

The energy expenditure side: adaptive thermogenesis

Weight loss of any kind lowers resting energy expenditure beyond what the drop in fat-free mass alone predicts. This is adaptive thermogenesis. The Biggest Loser follow-up (Fothergill 2016) measured it six years after the competition: resting metabolic rate ran about 500 kcal/day below what body composition predicted . Leibel and colleagues found the same direction of effect decades earlier in tightly controlled inpatient over- and under-feeding studies, so adaptive thermogenesis looks like a stable response to negative energy balance .

So the calorie deficit shrinks as weight falls. If intake also drifts up as appetite suppression fades, the deficit closes and the curve flattens. The plateau is the equilibrium the system settles into at a given dose.

What actually changes the curve

Three lever categories have published evidence behind them.

• Dose escalation within label. Higher doses delay the bend, and the dose-response curve in SURMOUNT-1 shows it directly: about -15.0 percent at 5 mg and about -20.9 percent at 15 mg by week 72 . Ramp with attention to nausea and, for compounded product, the FDA dosing-error guidance; a GLP-1 ramp planner lays out the labeled step schedule .
• Combination strategies. Adding amylin signaling (CagriSema, REDEFINE-1) or glucagon-receptor activity (retatrutide, phase 2) extends weight loss past what GLP-1 monotherapy delivers.
• Resistance training and higher protein intake during the active loss phase. Direct trials against a GLP-1 backdrop are still thin, but resistance training and adequate protein are well established for preserving fat-free mass during a calorie deficit.

The discontinuation question: what happens off-drug

STEP-1 had a randomized withdrawal extension. Participants who stopped semaglutide regained about two-thirds of the lost weight by week 120, one year after the 68-week trial ended, with cardiometabolic markers drifting back toward baseline . SURMOUNT-4 ran the same design for tirzepatide: the group switched to placebo regained weight while those who stayed on drug held and extended their loss . Weight settles back toward its prior setpoint once receptor activation stops.

This is why the labeled indication frames obesity as a chronic condition: long-term therapy for weight management, the same way high blood pressure or high cholesterol get managed over years.

What this means for people using these drugs

A plateau tells you the drug has reached the equilibrium your current dose, training, and intake support. It does not mean adherence slipped, and on its own it is not a reason to push the dose past the label without a prescriber. Compounded GLP-1 products carry a risk labeled pens do not: the FDA has logged repeated dosing errors with compounded semaglutide and tirzepatide, usually from confusing milligrams, milliliters, and units . Getting that conversion right with a reconstitution calculator is the fix.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 15 entries, primary canon (PubMed, PubMed Central, ClinicalTrials.gov, FDA) plus one manufacturer topline announcement acknowledged inline, last reviewed 2026-07-08.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.